LGND: Ligand Pharmaceuticals Incorporated Stocks News on April 25, 2025

Ligand to Report First Quarter 2025 Financial Results on May 8, 2025

LGND

GlobeNewswire

16 hours ago

Ligand to Report First Quarter 2025 Financial Results on May 8, 2025

LGND

Zacks Small Cap Research

2 days ago

LGND: Pelthos To Become Public Company

LGND

Argus Research

2 days ago

LGND: What does Argus have to say about LGND?

LGND

MT Newswires

7 days ago

Sector Update: Health Care Stocks Softer Thursday Afternoon

LGND

MT Newswires

7 days ago

Update: Ligand Pharmaceuticals to Merge Units With Channel Therapeutics to Launch Pelthos Therapeutics

LGND

MT Newswires

7 days ago

Top Midday Gainers

LGND

MT Newswires

8 days ago

Ligand Pharmaceuticals to Merge Units With Channel Therapeutics to Launch Pelthos Therapeutics

Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics

LGND

GlobeNewswire

8 days ago

Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics

LGND

Benzinga

8 days ago

EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity

LGND

Argus Research

9 days ago

LGND: Raising target price to $112.00

LGND

MT Newswires

15 days ago

Stifel Initiates Ligand Pharmaceuticals at Buy With $143 Price Target

LGND

Argus Research

16 days ago

LGND: Lowering target price to $102.00

LGND

Argus Research

23 days ago

LGND: Lowering target price to $110.00

LGND

Argus Research

a month ago

LGND: Raising target price to $115.00

Top March 2025 Stocks Estimated To Be Trading Below Their Intrinsic Value

LGND

Simply Wall St.

2 months ago

Top March 2025 Stocks Estimated To Be Trading Below Their Intrinsic Value

LGND

Argus Research

2 months ago

LGND: Lowering target price to $121.00

Ligand to Participate in March Investor Conferences

LGND

GlobeNewswire

2 months ago

Ligand to Participate in March Investor Conferences

LGND

Zacks Small Cap Research

2 months ago

LGND: First Steps into Cell & Gene Therapy

LGND

MT Newswires

2 months ago

Oppenheimer Adjusts Price Target on Ligand Pharmaceuticals to $142 From $151, Maintains Outperform Rating

LGND

MT Newswires

2 months ago

RBC Raises Price Target on Ligand Pharmaceuticals to $155 From $143, Keeps Outperform Rating

LGND

GuruFocus.com

2 months ago

Ligand Pharmaceuticals Inc (LGND) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

LGND

MT Newswires

2 months ago

Ligand Pharmaceuticals' Q4 Core Adjusted Net Income, Total Revenue Rise; 2025 Guidance Set

LGND

Associated Press Finance

2 months ago

Ligand: Q4 Earnings Snapshot

Ligand Reports Fourth Quarter and Full Year 2024 Financial Results

LGND

GlobeNewswire

2 months ago

Ligand Reports Fourth Quarter and Full Year 2024 Financial Results

LGND

GuruFocus.com

2 months ago

Ligand Pharmaceuticals Inc (LGND) Q4 2024: Everything You Need To Know Ahead Of Earnings

LGND

Argus Research

2 months ago

LGND: Lowering target price to $125.00

Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences

LGND

GlobeNewswire

2 months ago

Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences

LGND

Argus Research

2 months ago

LGND: Raising target price to $126.00

Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

LGND

Business Wire

2 months ago

Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

LGND

Business Wire

3 months ago

Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

LGND

Argus Research

3 months ago

LGND: Lowering target price to $123.00

LGND

Argus Research

3 months ago

LGND: Raising target price to $124.00

LGND

Argus Research

3 months ago

LGND: Raising target price to $123.00

LGND

Argus Research

3 months ago

LGND: Lowering target price to $114.00

LGND

Zacks Small Cap Research

3 months ago

Zacks Small Cap Research 2024 Initiations and Best Ideas for 2025

LGND

Simply Wall St.

4 months ago

Ligand Pharmaceuticals (NASDAQ:LGND) shareholders have earned a 59% return over the last year

LGND

Argus Research

4 months ago

LGND: Lowering target price to $119.00

LGND

Argus Research

4 months ago

LGND: Raising target price to $126.00

LGND

Zacks Small Cap Research

4 months ago

LGND: 2025 View Calls for 17% Topline Growth

Ligand price target raised to $151 from $135 at Oppenheimer

LGND

TipRanks

4 months ago

Ligand price target raised to $151 from $135 at Oppenheimer

LGND

MT Newswires

4 months ago

Oppenheimer Adjusts Ligand Pharmaceuticals Price Target to $151 From $135, Maintains Outperform Rating

LGND

MT Newswires

4 months ago

RBC Raises Price Target on Ligand Pharmaceuticals to $143 From $141, Keeps Outperform Rating

LGND

Argus Research

4 months ago

LGND: Lowering target price to $125.00

LGND

MT Newswires

4 months ago

Ligand Pharmaceuticals Issues 2025 Guidance; 2024 Forecast Reaffirmed

Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance

LGND

Business Wire

4 months ago

Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance

LGND

Argus Research

5 months ago

LGND: Lowering target price to $126.00

LGND

MT Newswires

5 months ago

RBC Lifts Price Target on Ligand Pharmaceuticals to $141 From $140, Keeps Outperform Rating

LGND

Simply Wall St.

5 months ago

Ligand Pharmaceuticals (NASDAQ:LGND) Shareholders Should Be Cautious Despite Solid Earnings

Ligand to Present at Stifel 2024 Healthcare Conference

LGND

Business Wire

5 months ago

Ligand to Present at Stifel 2024 Healthcare Conference

LGND

Argus Research

5 months ago

LGND: Raising target price to $127.00

LGND

Zacks Small Cap Research

5 months ago

LGND: 3Q Sales Surprise to the Upside

Ligand Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

LGND

Simply Wall St.

6 months ago

Ligand Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

LGND

Simply Wall St.

6 months ago

Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Intrinsic Value Is Potentially 99% Above Its Share Price

LGND

GuruFocus.com

6 months ago

Ligand Pharmaceuticals Inc (LGND) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...

LGND

MT Newswires

6 months ago

Sector Update: Health Care Stocks Rise Late Afternoon

LGND

MT Newswires

6 months ago

Ligand Shares Rise After Q3 Tops Expectations, Guidance Raised

LGND

Associated Press Finance

6 months ago

Ligand: Q3 Earnings Snapshot

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

LGND

Business Wire

6 months ago

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

LGND

GuruFocus.com

6 months ago

Ligand Pharmaceuticals Inc (LGND) Q3 2024: Everything You Need To Know Ahead Of Earnings

LGND

Argus Research

6 months ago

LGND: Lowering target price to $117.00

Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston

LGND

Business Wire

6 months ago

Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston

Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024

LGND

Business Wire

6 months ago

Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer

LGND

GlobeNewswire

6 months ago

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer

LGND

GuruFocus.com

7 months ago

Ligand Pharmaceuticals Inc (LGND) Q2 2024 Earnings Call Highlights: Robust Revenue Growth Amid ...

LGND

Zacks Small Cap Research

7 months ago

LGND: Initiating Coverage – A Prince Among Royalty

LGND

Argus Research

7 months ago

LGND: Raising target price to $108.00

LGND

MT Newswires

7 months ago

Oppenheimer Initiates Ligand Pharmaceuticals at Outperform With $135 Price Target

LGND

Simply Wall St.

7 months ago

Can Mixed Fundamentals Have A Negative Impact on Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Current Share Price Momentum?

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

LGND

Business Wire

8 months ago

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

LGND

Argus Research

8 months ago

LGND: Raising target price to $112.00

Insider Sale: President & COO Matthew Korenberg Sells 18,858 Shares of Ligand ...

LGND

GuruFocus.com

8 months ago

Insider Sale: President & COO Matthew Korenberg Sells 18,858 Shares of Ligand ...

LGND

Argus Research

8 months ago

LGND: Raising target price to $110.00

Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference

LGND

Business Wire

8 months ago

Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference

LGND

Simply Wall St.

8 months ago

Ligand Pharmaceuticals (NASDAQ:LGND) Shareholders Should Be Cautious Despite Solid Earnings

Private Capital's Strategic Moves Highlight Ligand Pharmaceuticals in Q2 2024

LGND

GuruFocus.com

8 months ago

Private Capital's Strategic Moves Highlight Ligand Pharmaceuticals in Q2 2024

LGND

MT Newswires

8 months ago

Ligand Pharmaceuticals Insider Sold Shares Worth $1,797,133, According to a Recent SEC Filing

LGND

GuruFocus.com

8 months ago

Insider Buying: CEO Todd Davis Acquires Shares of Ligand Pharmaceuticals Inc (LGND)

Ligand Pharmaceuticals Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

LGND

Simply Wall St.

9 months ago

Ligand Pharmaceuticals Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

LGND

MT Newswires

9 months ago

Ligand Pharmaceuticals Q2 Adjusted Earnings Fall, Revenue Increases; Reaffirms Full-Year Guidance

How These Two Lesser-Known Biotech Names Obliterated Sales Expectations

LGND

Investor's Business Daily

9 months ago

How These Two Lesser-Known Biotech Names Obliterated Sales Expectations

LGND

Associated Press Finance

9 months ago

Ligand: Q2 Earnings Snapshot

Ligand Reports Second Quarter 2024 Financial Results

LGND

Business Wire

9 months ago

Ligand Reports Second Quarter 2024 Financial Results

LGND

MT Newswires

9 months ago

Ligand Pharmaceuticals COO Matthew Korenberg to Step Down

Hidden Gems Undiscovered Companies with Strong Fundamentals For July 2024

LGND

Simply Wall St.

9 months ago

Hidden Gems Undiscovered Companies with Strong Fundamentals For July 2024

Undiscovered Gems In The United States For July 2024

LGND

Simply Wall St.

9 months ago

Undiscovered Gems In The United States For July 2024

LGND

MT Newswires

9 months ago

RBC Initiates Ligand Pharmaceuticals at Outperform With $130 Price Target

LGND

Argus Research

9 months ago

LGND: Raising target price to $107.00

Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024

LGND

Business Wire

9 months ago

Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024

LGND

Argus Research

9 months ago

LGND: Raising target price to $104.00

LGND

Argus Research

10 months ago

LGND: Raising target price to $96.00

Ligand Pharmaceuticals to acquire APEIRON Biologics for $100m

LGND

Pharmaceutical Technology

10 months ago

Ligand Pharmaceuticals to acquire APEIRON Biologics for $100m

LGND

MT Newswires

10 months ago

Ligand to Acquire Apeiron for $100 Million in Cash, Plus Up to $28 Million Based on Royalties

Ligand to buy Apeiron; Roche reports another TIGIT setback

LGND

BioPharma Dive

10 months ago

Ligand to buy Apeiron; Roche reports another TIGIT setback

Ligand to Acquire APEIRON Biologics AG for $100 Million

LGND

Business Wire

10 months ago

Ligand to Acquire APEIRON Biologics AG for $100 Million

LGND

Argus Research

10 months ago

LGND: Raising target price to $89.00

Lifecore Biomedical Announces Cooperation Agreement with 22NW

LGND

GlobeNewswire

10 months ago

Lifecore Biomedical Announces Cooperation Agreement with 22NW

LGND

MT Newswires

10 months ago

Ligand Pharmaceuticals' Partner Gets US FDA Approval for Ohtuvayre to Treat Chronic Obstructive Pulmonary Disease

Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years

LGND

Business Wire

10 months ago

Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years

Bristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer

LGND

Zacks

10 months ago

Bristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer

Terns (TERN) Gains 13.6% YTD: Will the Momentum Continue?

LGND

Zacks

10 months ago

Latest Ligand Pharmaceuticals Incorporated (LGND) News on April 25, 2025

Share on Social Networks: